SAN DIEGO AND BEER-SHEVA, ISRAEL...July 9, 2013 -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev (BGU), have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus (HCV).
"We are pleased to be collaborating with Sorrento to develop our fully human anti-HCV antibody clones into potential anti-HCV therapeutics," said Leslie Lobel, M.D., Ph.D., a lecturer and vice chair of the Department of Microbiology, Immunology and Genetics in BGU's Faculty of Health Sciences. Dr. Lobel identified the antibody clones from patients who have recovered from HCV infections.
According to the Centers for Disease Control (CDC), more than 170 million people worldwide are chronically infected with Hepatitis C Virus (HCV), including approximately 3.2 million people in the United States.
This collaborative effort utilizes the respective strengths of each organization to create an important product opportunity consisting of therapeutic and/or prophylactic agents against HCV infections. Sorrento, a San Diego-based company, will be responsible for developing the anti-HCV antibody products.
"Sorrento has already achieved many successes using its proprietary G-MAB® library to identify, characterize and develop fully human antibodies against difficult targets relevant to infectious agents," said Henry Ji, Ph.D., president and chief executive officer of Sorrento.
"We are excited to be working with Dr. Lobel to add a program targeting HCV to our existing portfolio of therapeutic antibodies for the prevention and/or treatment of major infectious diseases." Doron Krakow, executive vice president of American Associates, Ben-Gurion University of the Negev said, "It is exciting that another medical breakthrough emanating from BGU's research laboratories will potentially become a product that could help people suffering from hepatitis.
"Dr. Lobel was a pioneer at BGU, born and educated in the U.S., who chose to establish his research in the Negev Desert rather than at a top American medical university, so this is a truly significant development," Krakow added.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company located in San Diego, California that is engaged in the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the United States, Europe and additional international markets. Sorrento Therapeutics' primary focus is oncology but it is also developing products for other indications, including inflammation, metabolic and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. More information is available at http://www.sorrentotherapeutics.com.
B.G. Negev Technologies and Applications Ltd. (BGN) is the technology transfer company of Ben-Gurion University of the Negev, responsible for the commercialization of know-how and inventions of the University's researchers. Through the development of novel technologies and creative partnering with industry and investors, BGN brings value to the technological marketplace. BGN files worldwide patent applications and manages BGU's large patent portfolio. For more information, please visit BGN Technologies.
American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision, creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe. With some 20,000 students on campuses in Beer-Sheva, Sede Boqer and Eilat in Israel's southern desert, BGU is a university with a conscience, where the highest academic standards are integrated with community involvement, committed to sustainable development of the Negev. AABGU is headquartered in Manhattan and has nine regional offices throughout the U.S. For more information, please visit http://www.aabgu.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.